BR112017021120A2 - forma de dosagem de combinação de um antagonista de receptor mu opioide e um agente opioide - Google Patents

forma de dosagem de combinação de um antagonista de receptor mu opioide e um agente opioide

Info

Publication number
BR112017021120A2
BR112017021120A2 BR112017021120-3A BR112017021120A BR112017021120A2 BR 112017021120 A2 BR112017021120 A2 BR 112017021120A2 BR 112017021120 A BR112017021120 A BR 112017021120A BR 112017021120 A2 BR112017021120 A2 BR 112017021120A2
Authority
BR
Brazil
Prior art keywords
opioid
dosage form
combination dosage
receptor antagonist
release
Prior art date
Application number
BR112017021120-3A
Other languages
English (en)
Inventor
Li Shaoling
Leung Manshiu
Zhang Hao
R. Thalladi Venkat
Mo Yun
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of BR112017021120A2 publication Critical patent/BR112017021120A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

a invenção proporciona uma composição sólida do axelopran antagonista de opioides mu periféricos e uma forma de dosagem de combinação do sulfato de axelopran antagonista de opioides mu em uma forma de liberação imediata e um agente analgésico de opioide que pode estar em uma liberação prolongada, liberação contínua, liberação modificada ou forma de liberação controlada e métodos de preparação dessa forma de dosagem de combinação.
BR112017021120-3A 2015-04-02 2016-03-31 forma de dosagem de combinação de um antagonista de receptor mu opioide e um agente opioide BR112017021120A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141981P 2015-04-02 2015-04-02
US62/141,981 2015-04-02
PCT/US2016/025176 WO2016161069A1 (en) 2015-04-02 2016-03-31 Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Publications (1)

Publication Number Publication Date
BR112017021120A2 true BR112017021120A2 (pt) 2018-07-03

Family

ID=55806767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021120-3A BR112017021120A2 (pt) 2015-04-02 2016-03-31 forma de dosagem de combinação de um antagonista de receptor mu opioide e um agente opioide

Country Status (26)

Country Link
US (4) US20160287573A1 (pt)
EP (1) EP3277278B1 (pt)
JP (2) JP6713483B2 (pt)
KR (1) KR20170132325A (pt)
CN (1) CN107820424B (pt)
AU (1) AU2016243691A1 (pt)
BR (1) BR112017021120A2 (pt)
CA (1) CA2980328A1 (pt)
CY (1) CY1122828T1 (pt)
DK (1) DK3277278T3 (pt)
ES (1) ES2774473T3 (pt)
HK (1) HK1247105A1 (pt)
HR (1) HRP20200432T1 (pt)
HU (1) HUE048785T2 (pt)
IL (1) IL254593A0 (pt)
LT (1) LT3277278T (pt)
ME (1) ME03671B (pt)
MX (1) MX2017012474A (pt)
PH (1) PH12017501767A1 (pt)
PL (1) PL3277278T3 (pt)
PT (1) PT3277278T (pt)
RS (1) RS60074B1 (pt)
RU (1) RU2017134794A (pt)
SI (1) SI3277278T1 (pt)
TW (1) TW201642856A (pt)
WO (1) WO2016161069A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017012474A (es) 2015-04-02 2018-01-11 Theravance Biopharma R&D Ip Llc Forma farmaceutica combinada de un antagonista de los receptores opioides mu y un agente opioide.
JP7222244B2 (ja) * 2017-08-08 2023-02-15 三菱ケミカル株式会社 医薬錠剤、およびその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
RU2004106619A (ru) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
CA2540308C (en) 2003-09-26 2013-08-06 Alza Corporation Drug coating providing high drug loading and methods for providing the same
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
BRPI0608392A2 (pt) * 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2366058T3 (es) * 2006-03-01 2011-10-14 Theravance, Inc. Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu.
CN101500542A (zh) * 2006-07-11 2009-08-05 共有药物有限公司 控释制剂
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
EP2294012B1 (en) * 2008-05-07 2014-07-09 Salix Pharmaceuticals, Ltd. Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
EP2429505B1 (en) * 2009-05-12 2015-11-04 BPSI Holdings, LLC. Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
IT1398930B1 (it) * 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
US20130224296A1 (en) 2010-09-03 2013-08-29 Bristol-Myers Squibb Company Drug Formulations Using Water Soluble Antioxidants
EP2670397B1 (en) 2011-02-01 2020-05-13 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
US9339489B2 (en) * 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
MX2017012474A (es) 2015-04-02 2018-01-11 Theravance Biopharma R&D Ip Llc Forma farmaceutica combinada de un antagonista de los receptores opioides mu y un agente opioide.

Also Published As

Publication number Publication date
JP6713483B2 (ja) 2020-06-24
DK3277278T3 (da) 2020-04-06
CA2980328A1 (en) 2016-10-06
PH12017501767A1 (en) 2018-06-11
WO2016161069A1 (en) 2016-10-06
US20180050028A1 (en) 2018-02-22
KR20170132325A (ko) 2017-12-01
JP2020073583A (ja) 2020-05-14
US10946009B2 (en) 2021-03-16
US10369142B2 (en) 2019-08-06
EP3277278B1 (en) 2020-01-08
RS60074B1 (sr) 2020-05-29
CN107820424A (zh) 2018-03-20
HUE048785T2 (hu) 2020-08-28
ME03671B (me) 2020-10-20
US20210161884A1 (en) 2021-06-03
US20190321350A1 (en) 2019-10-24
PL3277278T3 (pl) 2020-07-27
ES2774473T3 (es) 2020-07-21
CN107820424B (zh) 2020-07-28
TW201642856A (zh) 2016-12-16
EP3277278A1 (en) 2018-02-07
CY1122828T1 (el) 2021-05-05
JP2018513138A (ja) 2018-05-24
IL254593A0 (en) 2017-11-30
LT3277278T (lt) 2020-03-25
SI3277278T1 (sl) 2020-04-30
MX2017012474A (es) 2018-01-11
US20160287573A1 (en) 2016-10-06
RU2017134794A (ru) 2019-04-04
PT3277278T (pt) 2020-04-16
AU2016243691A1 (en) 2017-10-12
HK1247105A1 (zh) 2018-09-21
US11452723B2 (en) 2022-09-27
HRP20200432T1 (hr) 2020-06-12

Similar Documents

Publication Publication Date Title
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
HK1248218A1 (zh) 作為毒蕈碱m1受體和/或m4受體的激動劑的螺環化合物
BR112017018715A2 (pt) agonista de receptor de angiotensina ii para tratar fibrose pulmonar
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
BR112015006019A2 (pt) composto selecionado, composição farmacêutica, método para tratar uma doença ou distúrbio, uso de um composto, kit para tratar uma condição mediada por pim quinase e invenção.
IL247854B (en) Muscarinic receptor antagonists, preparations containing them and their uses
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
EP3515420C0 (en) PHARMACEUTICAL COMPOSITIONS FOR USE IN BLEPHARITIS THERAPY
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
MA40998A (fr) Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
IL261982B (en) A prophylactic and therapeutic preparation based on peroxaphthalate, especially a pharmaceutical preparation
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
PH12019500326A1 (en) Combination of fxr agonists
BR112015022513A2 (pt) produto e método para tratamento de diarreia
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
EP3332764A4 (en) BIOFILM TRAINING PREVENTION AGENT AND COMPOSITION FOR ORAL USE
BR112017021120A2 (pt) forma de dosagem de combinação de um antagonista de receptor mu opioide e um agente opioide
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
BR112016005589B8 (pt) Composição farmacêutica líquida, e, uso da mesma
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
CR20170125A (es) Composición farmacéutica sólica que comprende amlodipina y losartán

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]